New schizophrenia shot could offer cheaper alternative to abilify maintena
NCT ID NCT07547384
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a new injectable form of aripiprazole (SYH9096) to the approved drug Abilify Maintena® in 116 adults with stable schizophrenia. Participants receive five injections of each version, one month apart, to see if the new version reaches similar drug levels in the blood. The goal is to show the two are bioequivalent, meaning they work the same way in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aripiprazole injection (a long-acting antipsychotic medication)
- What this could lead to
- If successful, this could provide a more affordable or accessible version of a monthly injection that helps control schizophrenia symptoms.
- What could go wrong
- This is an early-stage bioequivalence study, not a test of effectiveness. The new injection may not be absorbed the same way in all patients, and side effects could differ.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?